|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/439 | |
| A61P 25/28 | |||
| C12Q 1/6883 |
| (11) | Patento numeris | 2768507 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 12797979.7 |
| Europos patento paraiškos padavimo data | 2012-10-18 | |
| (97) | Europos patento paraiškos paskelbimo data | 2014-08-27 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-12-11 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/IB2012/055692 |
| Data | 2012-10-18 |
| (87) | Numeris | WO 2013/057687 |
| Data | 2013-04-25 |
| (30) | Numeris | Data | Šalis |
| 201161549319 P | 2011-10-20 | US |
| (72) |
FEUERBACH, Dominik, CH
GOMEZ-MANCILLA, Baltazar, CH
HE, Yunsheng, US
JOHNS, Donald, US
LOPEZ-LOPEZ, Cristina, CH
MCALLISTER, Kevin Hall, CH
PEZOUS, Nicole, CH
SANDFORD, Lisa, CH
WEISS, Markus, CH
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT |
| BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT |